Podcast: The Future Of R&D Is Self-Driving

In this episode of the In Vivo podcast, visionary University of Toronto researcher Alan Aspuru-Guzik talks about the value of generative AI, automation and quantum computing in drug discovery. 

In Vivo Podcast
• Source: Shutterstock

Alan Aspuru-Guzik has managed, at a young age, to co-found four tech/biotech startups, is professor of chemistry and computer science at the University of Toronto, and sits on the boards of AI-driven biotech, Insilico Medicine. It would be challenging to identify his main project, as he is also chair of Toronto’s Vector Institute for Artificial Intelligence and director of Acceleration Consortium, two projects meant to guide the roll out of artificial intelligence safely and effectively, across a swath of industrial sectors and by a range of global stakeholders.

In this episode of the In Vivo podcast, Alan focuses on the value of generative AI, automation and quantum computing in drug discovery.

Timestamp:

Intro

1:20 - Aspuru-Guzik’s academic and career trajectory

3:40 - Generative AI for molecule creation

6:30 - Intrepid Labs: a self-driving lab that combines automation with machine learning to optimize drug formulation

11:10 - Collaborations with pharma, including work with Insilico Medicine

13:40 - The creative potential of generative AI in drug discovery

16:20 - Quantum computing and pharma

19:30 - Combining quantum power with the self-driving lab

22:00 - Ethics in pharma

26:30 - The future of drug discovery and development

More from Innovation

Rising Leaders 2025: How Christina Smolke Turned Research Into Real World Impact

 
• By 

The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By 

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By 

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By 

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.

More from In Vivo

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By 

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By 

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By 

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.